Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Willem Oosterlinck & Karel Decaestecker. (2018) Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy 18:5, pages 437-443.
Read now
Read now
Articles from other publishers (19)
Nora Astrain-Redin, Carmen Sanmartin, Arun K. Sharma & Daniel Plano. (2023) From Natural Sources to Synthetic Derivatives: The Allyl Motif as a Powerful Tool for Fragment-Based Design in Cancer Treatment. Journal of Medicinal Chemistry 66:6, pages 3703-3731.
Crossref
Crossref
Chao Ma, Dan Li, Rui Dang, Yongwei Gu, Aixue Li, Yunan Zhao, Fu Qi & Jiyong Liu. (2022) Metabolism, pharmacokinetics, and bioavailability of yuanhuacine in rat using LC–MS. Biomedical Chromatography 37:2.
Crossref
Crossref
Kelly Ward, Mark O Kitchen, Suresh-Jay Mathias, Farhat L Khanim & Richard T. Bryan. (2022) Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning. Frontiers in Surgery 9.
Crossref
Crossref
Binbin Jiao, Kunpeng Liu, Haitao Gong, Zhenshan Ding, Xin Xu, Jian Ren, Guan Zhang, Qingsong Yu & Zhihua Gan. (2022) Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. Journal of Controlled Release 347, pages 632-648.
Crossref
Crossref
Anqi Yao, Sarah J. Storr, Martyn Inman, Lucy Barwell, Christopher J. Moody & Stewart G. Martin. (2022) Cytotoxic and Radiosensitising Effects of a Novel Thioredoxin Reductase Inhibitor in Brain Cancers. Molecular Neurobiology 59:6, pages 3546-3563.
Crossref
Crossref
Sin-Woo Seong, Youngjae Shin, In Ho Chang & Jung Hoon Kim. (2022) The Present and Future of Intravesical Therapy in Bladder Cancer. The Korean Journal of Urological Oncology 20:2, pages 82-91.
Crossref
Crossref
Dong-Kun Li, Jing-Yi Tan, Wei Deng & Zheng-Yang Xu. (2021) Reduction of bis(5-alkyl-2-furyl)(2-nitroaryl)methane with aqueous titanium trichloride solution. Tetrahedron 99, pages 132407.
Crossref
Crossref
Vasiliy M. Muzalevskiy, Zoia A. Sizova & Valentine G. Nenajdenko. (2021) An Efficient Synthesis of 2-CF3-3-Benzylindoles. Molecules 26:16, pages 5084.
Crossref
Crossref
Yue Li, Long Zhao & Xiao-Feng Li. (2021) Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy. Frontiers in Oncology 11.
Crossref
Crossref
Marlene Mathuber, Michael Gutmann, Mery La Franca, Petra Vician, Anna Laemmerer, Patrick Moser, Bernhard K. Keppler, Walter Berger & Christian R. Kowol. (2021)
Development of a cobalt(
iii
)-based ponatinib prodrug system
. Inorganic Chemistry Frontiers 8:10, pages 2468-2485.
Crossref
Crossref
Ross King, Conall Hayes, Claire L Donohoe, Margaret R Dunne, Maria Davern & Noel E Donlon. (2021) Hypoxia and its impact on the tumour microenvironment of gastroesophageal cancers. World Journal of Gastrointestinal Oncology 13:5, pages 312-331.
Crossref
Crossref
Victoria L. Codony & Mahvash Tavassoli. (2021) Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer. Translational Oncology 14:3, pages 101017.
Crossref
Crossref
Florea Dumitrascu & Marc A. Ilies. 2021.
65
157
.
Yvain Gerard, Aurélien Voissière, Caroline Peyrode, Marie-Josephe Galmier, Elise Maubert, Donia Ghedira, Sebastien Tarrit, Vincent Gaumet, Damien Canitrot, Elisabeth Miot-Noirault, Jean-Michel Chezal & Valérie Weber. (2020) Design, synthesis and evaluation of targeted hypoxia-activated prodrugs applied to chondrosarcoma chemotherapy. Bioorganic Chemistry 98, pages 103747.
Crossref
Crossref
Sarah K. Beaver, Noel Mesa-Torres, Angel L. Pey & David J. Timson. (2019) NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1867:7-8, pages 663-676.
Crossref
Crossref
Roger M. Phillips, Paul M. Loadman & Guru Reddy. (2019) Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. Cancer Chemotherapy and Pharmacology 83:6, pages 1183-1189.
Crossref
Crossref
Amit Sharma, Jonathan F. Arambula, Seyoung Koo, Rajesh Kumar, Hardev Singh, Jonathan L. Sessler & Jong Seung Kim. (2019) Hypoxia-targeted drug delivery. Chemical Society Reviews 48:3, pages 771-813.
Crossref
Crossref
Timo K. Nykopp, Jose Batista da Costa, Miles Mannas & Peter C. Black. (2018) Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Current Urology Reports 19:12.
Crossref
Crossref
Kuojun Zhang, Dong Chen, Kun Ma, Xiaoxing Wu, Haiping Hao & Sheng Jiang. (2018) NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer. Journal of Medicinal Chemistry 61:16, pages 6983-7003.
Crossref
Crossref